Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Expiring drug patents are continuously driving innovation, as branded firms seek out new high-margin opportunities.
Examining the patent expirations by year can indicate which pharmaceutical companies face the most peril from loss of patent protection.
This chart shows which pharmaceutical companies face the most patent expirations this year.
The drug companies facing the most patent expirations this year are Takeda Pharms Usa, Santarus Inc, Celgene, Sanofi Aventis Us, Boehringer Ingelheim, Bayer Healthcare Llc, Abbvie, Allergan, Glaxosmithkline, and Novartis Pharms Corp.